HCA Healthcare said 209,777,472 of the 223,568,966 shares of voting common stock were represented in person or by proxy at its annual meeting of stockholders on April 23, 2026. The 9 director nominees were elected to one-year terms, expiring in 1.

1. 01

   HCA Healthcare said 209,777,472 of the 223,568,966 shares of voting common stock were represented in person or by proxy at its annual meeting of stockholders on April 23, 2026. The 9 director nominees were elected to one-year terms, expiring in 1.

2. 02

   The company said Thomas F. Frist III received 187,441,344 votes for and 7,941,596 against, and Nancy-Ann DeParle received 173,121,216 votes for and 22,234,733 against. Broker non-votes were 14,343,334 for every nominee.

3. 03

   HCA Healthcare said stockholders approved the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 192,731,533 votes for and 16,987,639 against. The non-binding advisory resolution on executive compensation was also approved, with 182,386,619 votes for and 12,758,446 against.

4. 04

   The company reported that the stockholder proposal on a report on healthcare consequences was not approved, with 21,156,498 votes for and 173,337,098 against. The stockholder proposal on shareholders' right to act by written consent was also not approved, with 42,842,519 votes for and 152,097,860 against.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.